Additionally, phase 1/2 trials of CAR T cells targeted against CD22 are underway, as well as preclinical work to identify other potential leukemia protein targets such as CRLF2, mixed lineage leukemia (MLL), and CD123. The gene discussed is KMT2A; the disease is leukemia.